PB 32 of 2012
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 3)
National Health Act 1953
___________________________________________________________________________
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 26 April 2012
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
1 Name of Instrument
(1) This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 3).
(2) This Instrument may also be cited as PB 32 of 2012.
2 Commencement
This Instrument commences on 1 May 2012.
3 Amendments to PB 79 of 2011
Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
Schedule 1 Amendments
[1] Schedule 1 Part 1, entry for Carboplatin in the form Solution for I.V. injection 50 mg in 5 mL with manner of administration Injection
omit:
Pfizer Australia Pty Ltd
PF
MP
D
[2] Schedule 1 Part 1, entry for Cisplatin
omit:
I.V. injection 10 mg in 10 mL
Injection
Pfizer Australia Pty Ltd
PF
MP
D
[3] Schedule 1 Part 1, entry for Doxorubicin in the form Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial with manner of administration Injection/intravesical
omit:
Adriamycin Solution
PF
MP
D
[4] Schedule 1 Part 1, entry for Doxorubicin
omit:
Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 20 mg in 10 mL single dose vial
Injection/ intravesical
Adriamycin Solution
PF
MP
D
[5] Schedule 1 Part 1, after entry for Doxorubicin - Pegylated Liposomal in the form Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL with manner of administration Injection and brand Caelyx
insert in the columns in the order indicated:
Lipodox
ZF
MP
C1568 C1795 C1796 C3905 C3910 C3911
D
[6] Schedule 1 Part 1, after entry for Doxorubicin - Pegylated Liposomal in the form Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL with manner of administration Injection and brand Caelyx
insert in the columns in the order indicated:
Lipodox 50
ZF
MP
C1568 C1795 C1796 C3905 C3910 C3911
D
[7] Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL with manner of administration Injection/intravesical
omit:
Pharmorubicin Solution
PF
MP
D
[8] Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL with manner of administration Injection/intravesical
omit:
Pharmorubicin Solution
PF
MP
D
[9] Schedule 1 Part 1, entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL with manner of administration Injection
omit:
I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL
Injection
Camptosar
PF
MP
C3184
D
Hospira Pty Limited
HH
MP
C3184
D
substitute:
I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL
Injection
Hospira Pty Limited
HH
MP
C3184
D
[10] Schedule 1 Part 1, entry for Mitozantrone
omit:
Injection 10 mg (as hydrochloride) in 5 mL
Injection
Pfizer Australia Pty Ltd
PF
MP
D
[11] Schedule 1 Part 1, entry for Mitozantrone in the form Injection 25 mg (as hydrochloride) in 12.5 mL with manner of administration Injection
omit:
Pfizer Australia Pty Ltd
PF
MP
D
[12] Schedule 1 Part 1, entry for Oxaliplatin in the form Powder for I.V. infusion 100 mg with manner of administration Injection
omit:
Winthrop Oxaliplatin
WA
MP
C3900 C3901 C3930 C3939
D
[13] Schedule 1 Part 1, entry for Vincristine in the form I.V. injection containing vincristine sulfate 1 mg in 1 mL with manner of administration Injection
omit:
Pfizer Australia Pty Ltd
PF
MP
D
[14] Schedule 2, entry for Ondansetron in the form I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL with manner of administration Injection
omit:
Pfizer Australia Pty Ltd
PF
EMP
C3050
1
0
[15] Schedule 2, entry for Ondansetron in the form I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL with manner of administration Injection
omit:
Pfizer Australia Pty Ltd
PF
EMP
C3050
1
0
[16] Schedule 3, omit entry for WA
[17] Schedule 5, before entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd
insert:
Bleomycin
Powder for injection containing bleomycin sulfate 15,000 I.U.
Injection
Bleo 15K
1
$34.35
$65.24
[18] Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd
omit from the column headed ‘Listed Drug’:
Bleomycin
[19] Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd
omit from the column headed ‘Form’:
Powder for injection containing bleomycin sulfate 15,000 I.U.
[20] Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd
omit from the column headed ‘Manner of Administration’:
Injection
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See http://www.frli.gov.au.
